Neuroproteomics

Williams, Kenneth R.; Nairn, Angus C.

doi:10.3390/books978-3-03928-107-7

dc.contributor.author	Williams, Kenneth R.	*
dc.contributor.author	Nairn, Angus C.	*
dc.date.accessioned	2021-02-11T20:51:18Z
dc.date.available	2021-02-11T20:51:18Z
dc.date.issued	2020	*
dc.date.submitted	2020-04-07 23:07:08	*
dc.identifier	44747	*
dc.identifier.uri	https://directory.doabooks.org/handle/20.500.12854/54529
dc.description.abstract	The Neuroproteomics Special Issue overviews the unique challenges that must be addressed to carry out meaningful MS/proteomics analyses on neural tissues and the technologies that are available to meet these challenges. The articles on Alzheimer’s disease, addiction, and schizophrenia illustrate how MS/proteomics technologies can be used to improve our ability to diagnose and understand the molecular basis for neurological diseases. Several articles will be of interest to investigators beyond the field of neurological disorders. The review on the discovery of biofluid biomarkers of neurodegenerative dementias will be of interest to investigators searching for other disease biomarkers. Similarly, the review on the role of neuroproteomics in elucidating mechanisms of drug addiction provides an overview of the utility of MS/proteomics approaches for addressing critical questions in addiction neuroscience that should be applicable to investigators involved in virtually any area of biomedical research. Likewise, the article on developing targeted MS approaches for quantifying postsynaptic density proteins will be useful for any investigator who wishes to design targeted assays for virtually any protein. Finally, the peroxidase-mediated proximity labeling technology, described in the article on mapping the proteome of the synaptic cleft, will be of interest to investigators interested in mapping other spatially restricted proteomes.	*
dc.language	English	*
dc.subject	R5-920	*
dc.subject	RC346-429	*
dc.subject.classification	thema EDItEUR::M Medicine and Nursing	en_US
dc.subject.other	n/a	*
dc.subject.other	analgesia	*
dc.subject.other	quantitative phosphoproteomics	*
dc.subject.other	neurodegeneration	*
dc.subject.other	neuron	*
dc.subject.other	neuronal circuits	*
dc.subject.other	mating	*
dc.subject.other	sex-specific differences	*
dc.subject.other	AMPA receptor complex	*
dc.subject.other	parallel reaction monitoring	*
dc.subject.other	splicing	*
dc.subject.other	phosphorylation	*
dc.subject.other	peptidylglycine ?-amidating monooxygenase	*
dc.subject.other	pherophorin	*
dc.subject.other	Alzheimer’s disease	*
dc.subject.other	neuroscience	*
dc.subject.other	yohimbine	*
dc.subject.other	synapses	*
dc.subject.other	adolescence	*
dc.subject.other	conformational antibody	*
dc.subject.other	opioid receptors	*
dc.subject.other	protein interaction networks	*
dc.subject.other	Alzheimer’s Disease	*
dc.subject.other	transmembrane AMPA receptor regulatory protein	*
dc.subject.other	neuroproteome	*
dc.subject.other	ethanol	*
dc.subject.other	U1 snRNP	*
dc.subject.other	mass spectroscopy	*
dc.subject.other	morphine	*
dc.subject.other	protein phosphatase-1	*
dc.subject.other	neuroproteomics	*
dc.subject.other	axons	*
dc.subject.other	reinstatement	*
dc.subject.other	DIA	*
dc.subject.other	voltage gated channels	*
dc.subject.other	prohormone convertase	*
dc.subject.other	postsynaptic density	*
dc.subject.other	neuroimmune	*
dc.subject.other	dendrites	*
dc.subject.other	carboxypeptidase	*
dc.subject.other	GPCR signaling	*
dc.subject.other	CaMKII	*
dc.subject.other	FGF14	*
dc.subject.other	SynCAM	*
dc.subject.other	nicotinic receptor	*
dc.subject.other	synaptic plasticity	*
dc.subject.other	plasma	*
dc.subject.other	serum	*
dc.subject.other	corticosterone	*
dc.subject.other	dopamine	*
dc.subject.other	Receptor-type tyrosine-protein phosphatase zeta	*
dc.subject.other	Ptprz1	*
dc.subject.other	PRM	*
dc.subject.other	cell type	*
dc.subject.other	schizophrenia	*
dc.subject.other	laser capture microdissection	*
dc.subject.other	synapse specificity	*
dc.subject.other	LC-MS/MS	*
dc.subject.other	mouse	*
dc.subject.other	drug abuse	*
dc.subject.other	synaptic cleft	*
dc.subject.other	striatum	*
dc.subject.other	Cadm	*
dc.subject.other	cytokine	*
dc.subject.other	spinophilin	*
dc.subject.other	PSD	*
dc.subject.other	trans-synaptic adhesion	*
dc.subject.other	nicotine	*
dc.subject.other	proximity labeling	*
dc.subject.other	biomarkers	*
dc.subject.other	addiction	*
dc.subject.other	PKA	*
dc.subject.other	synapse	*
dc.subject.other	proteome	*
dc.subject.other	signal peptide	*
dc.subject.other	ventral tegmental area	*
dc.subject.other	protein aggregation	*
dc.subject.other	cerebrospinal fluid	*
dc.subject.other	bioinformatics	*
dc.subject.other	progressive ratio	*
dc.subject.other	interactome	*
dc.subject.other	subtilisin	*
dc.subject.other	affinity chromatography	*
dc.subject.other	basal ganglia	*
dc.subject.other	cocaine	*
dc.subject.other	targeted proteomics	*
dc.subject.other	postsynaptic	*
dc.subject.other	mass spectrometry	*
dc.subject.other	connectome	*
dc.subject.other	quantitative mass spectrometry	*
dc.subject.other	biotinylation	*
dc.subject.other	proteomics	*
dc.subject.other	amphetamine	*
dc.subject.other	autism	*
dc.subject.other	data-independent acquisition	*
dc.subject.other	excitatory/inhibitory tone	*
dc.subject.other	neuropeptidomics	*
dc.subject.other	matrix metalloproteinase	*
dc.subject.other	cilia	*
dc.subject.other	R-PTP-zeta	*
dc.subject.other	cognitive impairment	*
dc.title	Neuroproteomics	*
dc.type	book
oapen.identifier.doi	10.3390/books978-3-03928-107-7	*
oapen.relation.isPublishedBy	46cabcaa-dd94-4bfe-87b4-55023c1b36d0	*
oapen.relation.isbn	9783039281077	*
oapen.relation.isbn	9783039281060	*
oapen.pages	318	*
oapen.edition	1st	*

Fichier(s) constituant ce document

Fichiers	Taille	Format	Vue
Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Imported or submitted locally

Afficher la notice abrégée

Excepté là où spécifié autrement, la license de ce document est décrite en tant que https://creativecommons.org/licenses/by-nc-nd/4.0/